New genetic panel could personalize cancer treatment
NCT ID NCT07555639
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study enrolls 4,000 people with breast, ovarian, or colorectal cancer to test a comprehensive genetic panel. The panel looks for inherited cancer risks and tumor mutations that may affect drug sensitivity. Researchers aim to validate these genetic findings to potentially guide more personalized treatment decisions in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Genomic profile (NGS gene panel)
- What this could lead to
- If successful, this could improve personalized cancer care by better matching treatments to a patient's genetic profile.
- What could go wrong
- This is an early feasibility study, not a treatment trial. It may not directly improve outcomes, and the panel's accuracy needs validation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione Policlinico Universitario Agostino Gemelli, IRCCS
Roma, Roma, 00136, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Digital nurse companion: could an app ease the burden of chronic illness?